NDA 022104 · Osmotica Pharm US
Venlafaxine Hydrochloride
Venlafaxine Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
May 20, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
231
58 Phase 3, 14 recruiting
FAERS reports
72,835
61,305 serious, 10,429 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored...
What it is approved for
From the label in effect Jul 31, 2025.
Venlafaxine Extended Release Tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) 1.1 Major Depressive Disorder Venlafaxine Extended Release Tablets (venlafaxine hydrochloride) are indicated for the treatment of major depressive disorder (MDD). Efficacy of venlafaxine in MDD was shown in both short-term trials and a longer-term trial in MDD [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. 1.2 Social Anxiety Disorder Venlafaxine Extended Release Tablets are indicated for the treatment of Social Anxiety Disorder (SAD), also known as Social Phobia, as defined in DSM-IV. Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious...
Mechanism: The mechanism of the antidepressant action of venlafaxine in humans is believed to be associated with its potentiation of neurotransmitter activity in the CNS. Preclinical studies have shown that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 20, 2008 Original approval · Type 3 - New Dosage Form Other Important Information from FDASummary ReviewLetter
4 products under this application
- VENLAFAXINE HYDROCHLORIDE · VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- VENLAFAXINE HYDROCHLORIDE · VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- VENLAFAXINE HYDROCHLORIDE · VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- VENLAFAXINE HYDROCHLORIDE · VENLAFAXINE HYDROCHLORIDE EQ 225MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Venlafaxine" as an intervention, any sponsor and status, largest first.
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- International Study to Predict Optimised Treatment - in DepressionPivotal-lookingStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00693849 · 2,688 participants (planned) · Start Sep 2008 · Primary completion Dec 2019
Drug: Escitalopram; Sertraline and 1 more · For: Major Depressive Disorder
Sites: Colton, California; Mission Viejo, California; Stanford, California · 20 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed PatientsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00474708 · 1,151 participants · Start Apr 2007 · Primary completion Mar 2008
Drug: Effexor; SSRI · For: Major Depressive Disorder
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 26 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective5,934
- nausea4,685
- toxicity to various agents4,577
- off label use4,575
- fatigue4,433
- headache3,971
- completed suicide3,361
- drug interaction3,354
- dizziness3,200
- diarrhoea2,938
- pain2,721
- depression2,711
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 131 |
| 2005 | 120 |
| 2006 | 47 |
| 2007 | 51 |
| 2008 | 197 |
| 2009 | 467 |
| 2010 | 879 |
| 2011 | 1,248 |
| 2012 | 1,814 |
| 2013 | 1,947 |
| 2014 | 2,114 |
| 2015 | 3,131 |
| 2016 | 3,608 |
| 2017 | 4,342 |
| 2018 | 5,485 |
| 2019 | 6,254 |
| 2020 | 6,194 |
| 2021 | 5,696 |
| 2022 | 5,666 |
| 2023 | 6,286 |
| 2024 | 6,589 |
| 2025 | 6,040 |
| 2026 | 4,528 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
Henssler J, Schmidt Y, Schmidt U, et al. · Lancet Psychiatry 2024 · Systematic Review, Meta-Analysis
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
Furukawa TA, Cipriani A, Cowen PJ, et al. · Lancet Psychiatry 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Probiotics for adults with major depressive disorder compared with antidepressants: a systematic review and network meta-analysis.
Zhao S, Liang S, Tao J, et al. · Nutr Rev 2025 · Systematic Review, Comparative Study
Sponsor: Osmotica Pharm US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.